| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:2669-2677.)
© 2007 American Heart Association, Inc.
Coronary Heart Disease |
From the Division of Cardiology, Duke Clinical Research Institute (P.T., Y.L., L.G.B., R.M.C., L.K.N., R.A.H., K.W.M.), Durham, NC; Linda and Jack Gill Heart Institute (S.R.S.), University of Kentucky, Lexington, Ky; Krankenhaus Düren (D.C.G.), Düren, Germany; Green Lane Cardiovascular Service (H.D.W.), Auckland City Hospital, Auckland, New Zealand; Baylor College of Medicine (N.S.K.), Houston, Tex; Flinders Medical Centre (P.E.A.), Adelaide, Australia; Canadian Heart Research Centre and Terrence Donnelly Heart Center (A.L., S.G.G.), St. Michaels Hospital, University of Toronto, Toronto, Ontario, Canada; Texas Heart Institute (J.J.F.), St. Lukes-Episcopal Hospital, Houston, Tex; and Brigham and Womens Hospital (E.M.A.), Boston, Mass.
Correspondence to Pierluigi Tricoci, MD, MHS, PhD, Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705. E-mail trico001{at}dcri.duke.edu
Received January 12, 2007; accepted September 14, 2007.
Background— Optimal timing for an early invasive strategy in patients with non–ST-segment–elevation acute coronary syndrome remains unclear. We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non–ST-segment–elevation acute coronary syndrome who underwent angiography within 48 hours of admission.
Methods and Results— Data from 10 027 patients enrolled in the Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial were analyzed. Patients were grouped by 6-hour intervals of time from hospital admission to coronary angiography. Primary outcomes were 30-day death or myocardial infarction, in-hospital Thrombolysis In Myocardial Infarction (TIMI) and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) major bleeding, and blood transfusion. Adjusted estimates of event rates were obtained by use of a multivariable methodology that included possible confounders through baseline and accounted for propensity of time to angiography. The landmark method was used to calculate odds ratios and 95% confidence intervals of outcomes for each time period adjusted for baseline and postbaseline clinical events. Overall, 9216 patients (92%) underwent angiography, 6352 (63%) within 48 hours. Unadjusted and adjusted rates of death/myocardial infarction increased with increasing time to angiography. The adjusted odds ratio for death/myocardial infarction in patients receiving angiography in <6 hours was 0.56 (95% confidence interval 0.41 to 0.74), whereas after 30 hours, there was no significant benefit compared with further delayed angiography. Major bleeding and transfusion did not vary significantly across time-to-angiography intervals.
Conclusions— A decrease in the time to coronary angiography was associated with fewer ischemic outcomes and no increase in bleeding. Randomized clinical trials are needed to provide definitive evidence on optimal timing of coronary angiography but are difficult to design and conduct. Ongoing trials should instead clarify whether delaying angiography to administer aggressive upstream antithrombotic therapies is effective in the current setting of non–ST-segment–elevation acute coronary syndrome management.
This article has been cited by other articles:
![]() |
J. P. Piccini, M. Zhang, K. Pieper, S. D. Solomon, S. M. Al-Khatib, F. Van de Werf, M. A. Pfeffer, J. J.V. McMurray, R. M. Califf, and E. J. Velazquez Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial Eur. Heart J., October 23, 2009; (2009) ehp425v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Mehta, C. B. Granger, W. E. Boden, P. G. Steg, J.-P. Bassand, D. P. Faxon, R. Afzal, S. Chrolavicius, S. S. Jolly, P. Widimsky, et al. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes N. Engl. J. Med., May 21, 2009; 360(21): 2165 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
R K Riezebos, E Ronner, E ter Bals, T Slagboom, P C Smits, J M ten Berg, F Kiemeneij, G Amoroso, M S Patterson, M J Suttorp, et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes Heart, May 1, 2009; 95(10): 807 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1095 - 1103. [Full Text] [PDF] |
||||
![]() |
L. Mauri and S.-L. T. Normand Studies of Drug-Eluting Stents: To Each His Own? Circulation, April 22, 2008; 117(16): 2047 - 2050. [Full Text] [PDF] |
||||
![]() |
Early Angiography for High-Risk Acute Coronary Syndromes Journal Watch Cardiology, February 6, 2008; 2008(206): 2 - 2. [Full Text] |
||||
![]() |
S.-L. T. Normand Evaluating the Optimal Timing of Angiography: Landmark or off the Mark? Circulation, December 4, 2007; 116(23): 2656 - 2657. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |